<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668144</url>
  </required_header>
  <id_info>
    <org_study_id>SMF-02</org_study_id>
    <nct_id>NCT04668144</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI</brief_title>
  <acronym>SWAP-6</acronym>
  <official_title>Pharmacodynamic and Pharmacokinetic Profiles on Switching From Cangrelor to Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet -6 (SWAP-6) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scott R. MacKenzie Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet&#xD;
      inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients&#xD;
      undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor&#xD;
      prasugrel is commonly utilized, there is very limited data on the optimal approach for&#xD;
      switching between these therapies. The overarching aim of this investigation is to rule out a&#xD;
      drug drug interaction (DDI) when cangrelor and prasugrel are concomitantly administered in&#xD;
      patients undergoing coronary stenting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet&#xD;
      inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients&#xD;
      undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor&#xD;
      prasugrel is commonly utilized, there is very limited data on the optimal approach for&#xD;
      switching between these therapies. In particular, ruling out a drug-drug interaction (DDI) is&#xD;
      critical to this extent as the presence of a DDI would translate into reduced or abolished&#xD;
      antiplatelet effects exposing these acute patients to an increased thrombotic risk. There is&#xD;
      an unmet need to better elucidate pharmacodynamic profiles associated with the transition&#xD;
      from cangrelor to prasugrel therapy. Of note, prasugrel has recently gone off patent and the&#xD;
      availability of a generic formulation will favorably impact its use. Pharmacodynamic studies&#xD;
      provide some support on the safety of administering prasugrel at the start of cangrelor&#xD;
      infusion. However, the available data does not allow to rule out a DDI given that there was&#xD;
      no comparator arm in which prasugrel was either given alone or at the end of cangrelor&#xD;
      infusion. The methodological approach for this assessment should rely on comprehensive&#xD;
      pharmacodynamics investigations aimed to assess levels of P2Y12 receptor inhibition,&#xD;
      pharmacokinetic investigations to assess systemic levels of the drug/drug metabolite, and&#xD;
      mechanistic investigations by assessment of levels of P2Y12 receptor gene expression. The&#xD;
      overarching aim of this investigation is to rule out a DDI when cangrelor and prasugrel are&#xD;
      concomitantly administered in patients undergoing coronary stenting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Laboratory personnel will be blinded to treatment assignments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity measured by VerifyNow</measure>
    <time_frame>4 hours</time_frame>
    <description>The primary end point of the study will be the non-inferiority in P2Y12 reaction units (PRU) of cangrelor plus prasugrel concomitantly administered at the start of PCI versus prasugrel only administered at the start of PCI.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel only administered at the start of PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel + Cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cangrelor plus prasugrel concomitantly administered at the start of PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cangrelor followed by Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cangrelor administered at the start of PCI plus prasugrel administered at the end of the cangrelor infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor</intervention_name>
    <description>Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.</description>
    <arm_group_label>Cangrelor followed by Prasugrel</arm_group_label>
    <arm_group_label>Prasugrel + Cangrelor</arm_group_label>
    <other_name>Kengreal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration</description>
    <arm_group_label>Cangrelor followed by Prasugrel</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_label>Prasugrel + Cangrelor</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with NSTE-ACS (UA or NSTEMI) undergoing PCI. NSTE-ACS will be defined as the&#xD;
             presence of cardiac ischemic symptoms with ischemic changes (but not ST-segment&#xD;
             elevation) on electrocardiogram with or without a positive troponin. However, normal&#xD;
             electrocardiograms will be acceptable if the investigator will consider an ACS&#xD;
             presentation likely.&#xD;
&#xD;
          -  Age between 18 and 75 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Age &gt;75 years&#xD;
&#xD;
          -  Weight &lt;60 Kg&#xD;
&#xD;
          -  ST-segment elevation myocardial infarction&#xD;
&#xD;
          -  On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel,&#xD;
             ticagrelor) in past 7 days&#xD;
&#xD;
          -  Known allergies to prasugrel or cangrelor&#xD;
&#xD;
          -  Considered at high risk for bleeding&#xD;
&#xD;
          -  History of ischemic or hemorrhagic stroke or transient ischemic attack&#xD;
&#xD;
          -  On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban,&#xD;
             apixaban, edoxoban)&#xD;
&#xD;
          -  Planned treatment with glycoprotein IIb/IIIa inhibitors (only bailout use allowed)&#xD;
&#xD;
          -  Fibrinolytics within 24 hours&#xD;
&#xD;
          -  Known platelet count &lt;80x106/mL&#xD;
&#xD;
          -  Known hemoglobin &lt;10 g/dL&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Known end stage renal disease on hemodialysis&#xD;
&#xD;
          -  Known severe hepatic dysfunction&#xD;
&#xD;
          -  Intubated patients (prior to randomization)&#xD;
&#xD;
          -  Pregnant females [women of childbearing age must use reliable birth control (i.e. oral&#xD;
             contraceptives) while participating in the study]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Franchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Franchi, MD</last_name>
    <phone>904-244-2060</phone>
    <email>francesco.franchi@jax.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Goosen</last_name>
    <phone>9042445617</phone>
    <email>andrea.goosen@jax.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Franchi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

